MyFinsight
Home
Blog
About
Marketable securities
$196,323K
(228.76%↑ Y/Y)
Cash and cash
equivalents
$18,905K
(28.68%↑ Y/Y)
Prepaid and other
current assets
$5,731K
(345.30%↑ Y/Y)
Accounts receivable
$6K
(-93.02%↓ Y/Y)
Total current assets
$220,965K
(191.59%↑ Y/Y)
Investment in angel
pharmaceuticals
$15,107K
(28.09%↑ Y/Y)
Other assets
$1,713K
(173.64%↑ Y/Y)
Property and equipment,
net
$830K
(233.33%↑ Y/Y)
Operating lease
right-of-use asset
$659K
(-34.88%↓ Y/Y)
Total assets
$239,274K
(167.46%↑ Y/Y)
Total liabilities and
stockholders' equity
$239,274K
(167.46%↑ Y/Y)
Total stockholders'
equity
$225,328K
(180.86%↑ Y/Y)
Total liabilities
$13,946K
(51.05%↑ Y/Y)
Accumulated deficit
-$443,944K
(-13.89%↓ Y/Y)
Accumulated other
comprehensive loss
-$1,293K
(-12.63%↓ Y/Y)
Additional paid-in capital
$670,557K
(42.31%↑ Y/Y)
Total current
liabilities
$13,672K
(60.75%↑ Y/Y)
Operating lease liability
$274K
(-62.36%↓ Y/Y)
Common stock 0.0001 par
value 290,000,000...
$8K
(14.29%↑ Y/Y)
Accrued and other
liabilities
$9,171K
(82.94%↑ Y/Y)
Accounts payable
$4,047K
(29.01%↑ Y/Y)
Operating lease liability
$454K
(27.89%↑ Y/Y)
Back
Back
Balance Sheet
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)
source: myfinsight.com